Skip to search formSkip to main content

BW 301U

Known as: BW-301U, BW301U 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1989
1989
A selected number of 1,3-diaminobenzo[f]quinazolines and 1,3-diamino-5,6-dihydrobenzo[f]quinazolines, which may be viewed as… Expand
Is this relevant?
1987
1987
Trimetrexate and BW301U (piritrexim isethionate), lipid-soluble inhibitors of dihydrofolate reductase, are potent inhibitors of… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Is this relevant?
1987
1987
Administration a la dose de 160 mg/m 2 deux fois par jour pendant 5 jours. Etude chez 35 malades. Effet «marginal» du piritrexim 
Is this relevant?
1987
1987
We have used a microtiter assay to study the toxicity of various folate analogs in a series of cultured human cell lines that… Expand
Is this relevant?
1986
1986
The lipid-soluble folate antagonist, 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidin e (piritrexim; BW301U… Expand
Is this relevant?
1985
1985
Three methotrexate (MTX)-resistant cell lines and their MTX-sensitive counterparts have been used to examine 2,4-diamino-6-(2,5… Expand
  • table 1
  • table 2
Is this relevant?
1985
1985
Treatment of B and T lymphoblastoid cell lines (SB and MOLT-4, respectively) and a promyelocytic leukemia cell line (HL-60) with… Expand
Is this relevant?
1982
1982
The human lymphoblastoid cell line, WIL-2, and a mouse cell line, 3T6R400, that overproduces a mutant dihydrofolate reductase… Expand
Is this relevant?
1980
1980
The synthesis of 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine (BW301U, 7) by a route that has general… Expand
Is this relevant?